ProofPilot, a NYC-based provider of clinical experience platform (CXP), raised an undisclosed amount in Series C funding.
The round was led by Sopris Capital with participation from Mitsui & Co. (U.S.A.), Inc.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Chris Venezia, ProofPilot provides a platform, StudyCoPilot, that centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. The products and services support key initiatives like improving DE&I, streamlining recruitment & retention, and easing site burden. The system has scaled its capabilities for enterprise use and has pharmaceutical clients deploying it globally.
Commenting on the news, Chris Venezia said: “Our strategic advisory board, comprising patients, research sites, and sponsors, is solving the right challenges and needs to modernize experiences for all stakeholders. This repeat investment from our Series B investors recognizes the market’s need and provides us with resources to scale and accelerate life-saving therapies.”
FinSMEs
11/07/2024